PD-L1 Polyclonal Antibody | Invitrogen PA5-28115 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

PD-L1 Polyclonal Antibody

catalog :

PA5-28115

quantity :

100 uL

price :

US 514.00

clonality :

polyclonal

host :

domestic rabbit

conjugate :

nonconjugated

reactivity :

human, mouse

application :

western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section

more info or order :

Invitrogen product webpage

citations: 16

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry; human; loading ...; fig 7a	Garcia Hernandez M, Uribe Uribe N, Espinosa González R, Kast W, Khader S, Rangel Moreno J. A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol. 2017;8:563 pubmed publisher
western blot; human; fig 1 western blot; mouse; fig 1	M L, P P, T K, M P, E S, J P, et al. Essential role of HDAC6 in the regulation of PD-L1 inÂ melanoma. Mol Oncol. 2016;10:735-750 pubmed publisher
	Dergham A, Vaz de Paula C, Nagashima S, Olandoski M, de Noronha L, Sotomaior V. Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study. J Pers Med. 2023;13: pubmed publisher
	Battaglia A, Sacco A, Aversa I, Santamaria G, Palmieri C, Botta C, et al. Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma. Front Cell Dev Biol. 2023;11:1208485 pubmed publisher
	Hamed M, Gouida M, Abd El Aziz S, El Sokkary A. Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. Heliyon. 2022;8:e09474 pubmed publisher
	Ng D, Li Z, Lee E, Kok J, Lee J, Koh J, et al. Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. NPJ Breast Cancer. 2022;8:44 pubmed publisher
	Ruiz Rodr xed guez A, Molina Vallejo M, Aznar Peralta I, Gonz xe1 lez Puga C, Ca xf1 as Garc xed a I, Gonz xe1 lez E, et al. Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream). Cancers (Basel). 2021;13: pubmed publisher
	Zhu J, Huang R, Yang R, Xiao Y, Yan J, Zheng C, et al. Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration. Cancer Cell Int. 2021;21:529 pubmed publisher
	Sreevalsan S, Döring M, Paszkowski Rogacz M, Brux M, Blanck C, Meyer M, et al. MLLT6 maintains PD-L1 expression and mediates tumor immune resistance. EMBO Rep. 2020;:e50155 pubmed publisher
	Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S, et al. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Commun Signal. 2020;18:112 pubmed publisher
	Lovly C, Boyd K, Gonzalez Ericsson P, Lowe C, Brown H, Hoffman R, et al. Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer. medRxiv. 2020;: pubmed publisher
	Johnson D, McDonnell W, Gonzalez Ericsson P, Al Rohil R, Mobley B, Salem J, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019;25:1243-1250 pubmed publisher
	Won H, Lee D, Yeon S, Ryu H, Kim G, Kwon S. HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma. Int J Oncol. 2019;55:499-512 pubmed publisher
	Jagoda E, Vasalatiy O, Basuli F, Opina A, Williams M, Wong K, et al. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Mol Imaging. 2019;18:1536012119829986 pubmed publisher
	Medina Enríquez M, Félix A, Ciudad C, Noe V. Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells. PLoS ONE. 2018;13:e0206818 pubmed publisher
	Lee D, Won H, Ryu H, Han J, Kwon S. The HDAC6 inhibitor ACY‑1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells. Int J Oncol. 2018;53:844-854 pubmed publisher

product information

Product Type :

Antibody

Product Name :

PD-L1 Polyclonal Antibody

Catalog # :

PA5-28115

Quantity :

100 uL

Price :

US 514.00

Clonality :

Polyclonal

Purity :

Antigen affinity chromatography

Host :

Rabbit

Reactivity :

Human

Applications :

Immunocytochemistry: 1:100-1:1,000, Immunohistochemistry (Frozen): Assay-dependent, Immunohistochemistry (Paraffin): 1:100-1:1,000, Western Blot: 1:500-1:3,000

Species :

Human

Isotype :

IgG

Storage :

Store at 4 C short term. For long term storage, store at -20 C, avoiding freeze/thaw cycles.

Description :

Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.

Immunogen :

Synthetic peptide corresponding to a region within amino acids 230 and 290 of CD274

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:100-1:1,000, Immunohistochemistry (Frozen): Assay-dependent, Immunohistochemistry (Paraffin): 1:100-1:1,000, Western Blot: 1:500-1:3,000

Aliases :

A530045L16Rik; B7 homolog 1; B7-H; B7h1; B7-H1; Cd274; CD274 antigen; CD274 molecule; PDCD1 ligand 1; Pdcd1l1; Pdcd1lg1; Pdl1; PD-L1; pdl-1; Programmed cell death 1 ligand 1; programmed death ligand 1; RGD1566211; sCD274; soluble CD274; soluble PD L1; sPD L1

more info or order :

Invitrogen product webpage